Delandistrogene moxeparvovec Disease Interactions

Administration of delandistrogene moxeparvovec in patients with hepatic impairment, acute liver disease, chronic hepatic conditions, or elevated GGT has not been studied. Treatment with this drug should be carefully considered in patients with preexisting-existing hepatic impairment or chronic hepatic viral infection as this population may be at increased risk of acute serious liver injury. Postpone administration of delandistrogene moxeparvovec in patients with acute liver disease until it is resolved or controlled. Elevated liver function tests are commonly reported in patients after treatment with this drug. Assess liver enzymes prior to treatment, and then monitor liver function weekly for 3 months after infusion, or until results are unremarkable.